Centessa Pharmaceuticals Plc (CNTA) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CNTA SEC filings page.
Centessa Pharmaceuticals Plc (CNTA) reported $15.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Centessa’s dominant mechanic is a development-stage cost base funded externally while research spending far exceeds commercial revenue.
In FY2025, R&D reached$172M against$15M of revenue, so the cost base remains built around development rather than commercial scale. Operating cash flow of-$193.8M nearly equaled FCF of-$194.2M , indicating that cash use is tied mainly to ongoing operations rather than heavy physical reinvestment.
Operating cash flow shifted from
Debt-to-equity eased from 0.3x in FY2023 to 0.2x in FY2025, so the expanding equity base is not being matched by proportionate debt growth. Yet financing inflow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Centessa Pharmaceuticals Plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Centessa Pharmaceuticals Plc held $577.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $193.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Centessa Pharmaceuticals Plc scores 60/100 among other emerging companies.
Centessa Pharmaceuticals Plc had 155M shares outstanding at the end of fiscal year 2025, against 133M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Centessa Pharmaceuticals Plc scores 30/100 among other emerging companies.
Centessa Pharmaceuticals Plc spent $172.2M on research and development in fiscal year 2025, which was 77.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Centessa Pharmaceuticals Plc scores 96/100 among other emerging companies.
Centessa Pharmaceuticals Plc reported revenue of $15.0M in fiscal year 2025, against none in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Centessa Pharmaceuticals Plc scores 78/100 among other emerging companies.
Centessa Pharmaceuticals Plc's operations used $193.8M of cash in fiscal year 2025, against $142.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Centessa Pharmaceuticals Plc scores 35/100 among other emerging companies.
Centessa Pharmaceuticals Plc's cash, cash equivalents and investments came to $577.1M at the end of fiscal year 2025, against $160.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Centessa Pharmaceuticals Plc scores 85/100 among other emerging companies.
Centessa Pharmaceuticals Plc scores 20.58, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.3B) relative to total liabilities ($160.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Centessa Pharmaceuticals Plc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Centessa Pharmaceuticals Plc reported a net loss of $197.5M while operations used $193.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Centessa Pharmaceuticals Plc reported an operating loss of $207.7M against $11.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Centessa Pharmaceuticals Plc generated $0 in revenue in Q1 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Centessa Pharmaceuticals Plc's EBITDA was -$79.5M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 160.3% from the same quarter a year earlier.
Centessa Pharmaceuticals Plc reported -$79.2M in net income in Q1 2026. This represents a decrease of 203.2% from the same quarter a year earlier.
Centessa Pharmaceuticals Plc earned -$0.52 per diluted share (EPS) in Q1 2026. This represents a decrease of 160.0% from the same quarter a year earlier. Against the prior quarter it is down 8.3%.
Cash & Balance Sheet
Centessa Pharmaceuticals Plc held $62.4M in cash against $110.4M in long-term debt as of Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Centessa Pharmaceuticals Plc's ROE was -16.3% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 9.5 percentage points from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
Centessa Pharmaceuticals Plc invested $59.9M in research and development in Q1 2026. This represents an increase of 79.1% from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
CNTA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | N/A | $0 | $0 | $15.0M | N/A | $0 | $0 |
| R&D Expenses | $59.9M+79.1% | N/A | $41.6M+22.6% | $42.7M+30.2% | $33.4M+47.6% | N/A | $33.9M+20.3% | $32.8M-2.5% |
| SG&A Expenses | $19.9M+61.2% | N/A | $12.2M-2.2% | $11.9M+6.7% | $12.3M-8.2% | N/A | $12.5M+4.0% | $11.2M-16.3% |
| Operating Income | -$79.8M-159.2% | N/A | -$53.8M-15.9% | -$54.7M-24.3% | -$30.8M+14.7% | N/A | -$46.4M-15.4% | -$44.0M+6.5% |
| EBITDA | -$79.5M-160.3% | N/A | -$53.6M-16.0% | -$54.4M-24.4% | -$30.6M+14.8% | N/A | -$46.2M-15.5% | -$43.7M+6.5% |
| Interest Expense | $2.7M-5.1% | N/A | $2.9M+13.0% | $2.9M+14.2% | $2.9M+13.8% | N/A | $2.6M+0.6% | $2.5M+3.1% |
| Income Tax | $850K-39.2% | N/A | $166K-72.7% | $778K+10.4% | $1.4M+190.4% | N/A | $608K+121.5% | $705K+102.9% |
| Net Income | -$79.2M-203.2% | N/A | -$54.9M-29.0% | -$50.3M-14.9% | -$26.1M+31.3% | N/A | -$42.6M-10.1% | -$43.8M-76.1% |
| EPS (Basic) | -$0.52-160.0% | -$0.48+47.3% | -$0.41-10.8% | -$0.38+5.0% | -$0.20+47.4% | -$0.91-145.9% | -$0.37+7.5% | -$0.40-53.8% |
| EPS (Diluted) | -$0.52-160.0% | -$0.48+47.3% | -$0.41-10.8% | -$0.38+5.0% | -$0.20+47.4% | -$0.91-145.9% | -$0.37+7.5% | -$0.40-53.8% |
| Diluted Shares (Avg) | 154M+15.4% | N/A | 134M+15.4% | 134M+22.1% | 133M+33.2% | N/A | 116M+20.3% | 109M+15.1% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CNTA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $641.8M+21.6% | $687.5M+19.2% | $448.3M-26.5% | $492.1M+23.4% | $527.8M+60.8% | $576.8M+60.1% | $609.7M+61.6% | $398.8M+1.5% |
| Current Assets | $348.7M+0.3% | $367.9M-31.4% | $307.7M-45.9% | $300.4M-15.5% | $347.7M+22.2% | $536.4M+70.2% | $568.4M+71.0% | $355.5M+1.5% |
| Cash & Equivalents | $62.4M-40.6% | $61.3M-84.0% | $50.8M-87.1% | $44.2M-65.3% | $105.2M-11.0% | $383.2M+199.3% | $395.0M+130.3% | $127.4M-12.3% |
| Short-Term Investments | $214.2M+19.4% | $233.3M+135.7% | $195.4M+58.3% | $206.5M+23.3% | $179.3M+60.2% | $99.0M-23.0% | $123.4M+12.4% | $167.5M+5.7% |
| Long-Term Investments | $257.1M+83.1% | $282.5M | $102.8M | $153.4M | $140.4M | $0 | $0 | $0 |
| Total Liabilities | $154.4M+9.1% | $160.6M-8.3% | $146.7M+32.7% | $147.2M+31.6% | $141.6M+25.3% | $175.3M+41.3% | $110.6M-6.3% | $111.9M-3.8% |
| Current Liabilities | $36.6M+51.1% | $42.9M-26.0% | $29.1M+10.3% | $29.7M+11.0% | $24.2M-11.8% | $58.0M+47.3% | $26.4M-24.5% | $26.8M-21.0% |
| Non-Current Liabilities | $117.8M+0.4% | $117.7M+0.4% | $117.6M+39.7% | $117.5M+38.0% | $117.4M+37.2% | $117.3M+38.6% | $84.2M+1.4% | $85.1M+3.2% |
| Long-Term Debt | $110.4M+1.1% | $110.1M+1.1% | $109.8M+45.1% | $109.5M+43.2% | $109.3M+42.3% | $108.9M+43.9% | $75.7M+2.3% | $76.5M+4.4% |
| Total Equity | $487.3M+26.2% | $526.9M+31.2% | $301.6M-39.6% | $344.9M+20.2% | $386.2M+79.5% | $401.5M+70.0% | $499.1M+92.4% | $287.0M+3.7% |
| Retained Earnings | -$1.3B-24.7% | -$1.2B-20.0% | -$1.1B-27.7% | -$1.1B-27.6% | -$1.0B-28.3% | -$988.7M-31.3% | -$877.4M-22.5% | -$834.8M-23.2% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
CNTA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$72.2M-26.2% | -$55.8M-30.4% | -$58.3M-172.6% | -$22.5M+44.7% | -$57.2M-53.5% | -$42.8M-37.8% | -$21.4M+42.8% | -$40.6M+7.9% |
| Depreciation & Amortization | $239K+10.1% | $241K+4.8% | $237K+0.4% | $226K-4.2% | $217K-9.6% | $230K-6.5% | $236K-0.8% | $236K-0.4% |
| Stock-Based Compensation | $10.6M+34.0% | N/A | $7.2M-14.9% | $7.9M-7.7% | $7.9M-3.3% | N/A | $8.5M+11.8% | $8.6M+19.4% |
| Capital Expenditures | N/A | $11K | $234K+588.2% | N/A | N/A | $0-100.0% | $34K-20.9% | $0-100.0% |
| Free Cash Flow | N/A | -$55.8M-30.4% | -$58.5M-173.3% | N/A | N/A | -$42.8M-37.7% | -$21.4M+42.8% | -$40.6M+7.9% |
| Investing Cash Flow | $42.7M+119.2% | -$218.1M-972.5% | $61.9M+37.8% | -$40.0M+28.0% | -$222.4M-1426.7% | $25.0M+236.8% | $45.0M-7.7% | -$55.5M+22.0% |
| Financing Cash Flow | $30.5M+887.3% | $283.4M+9464.6% | $3.4M-98.6% | $1.6M-98.5% | $3.1M-70.6% | $3.0M-53.4% | $246.0M+1568.4% | $105.3M+877508.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CNTA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | -205.2% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | -174.2% | N/A | N/A | N/A |
| Return on Equity | -16.3%-9.5pp | N/A | -18.2%-9.7pp | -14.6%+0.7pp | -6.8%+10.9pp | N/A | -8.5%+6.4pp | -15.3%-6.3pp |
| Return on Assets | -12.3%-7.4pp | N/A | -12.2%-5.3pp | -10.2%+0.8pp | -5.0%+6.6pp | N/A | -7.0%+3.3pp | -11.0%-4.7pp |
| Current Ratio | 9.53-4.8x | 8.57-0.7x | 10.56-11.0x | 10.12-3.2x | 14.37+4.0x | 9.25+1.2x | 21.52+12.0x | 13.29+2.9x |
| Debt-to-Equity | 0.23-0.1x | 0.21-0.1x | 0.36+0.2x | 0.32+0.1x | 0.28-0.1x | 0.270.0x | 0.15-0.1x | 0.270.0x |
| Asset Turnover | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.030.0x | N/A | 0.00 | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals Plc CNTA | FY2025 | $15.0M | -$197.5M | N/A | $6.3B | 64/100 |
| Crinetics Pharmaceuticals CRNX | FY2025 | $7.7M | -$465.3M | N/A | $9.0B | 60/100 |
| Telix Pharmaceuticals Ltd ADR TLX | FY2025 | $803.8M | -$7.1M | -0.9% | $4.1B | 39/100 |
| Scholar Rock Holding SRRK | FY2025 | $0 | -$378.0M | N/A | $7.0B | — |
| Immunovant Inc IMVT | FY2026 | N/A | -$505.6M | N/A | $8.2B | — |
| Viking Therapeutics Inc VKTX | FY2025 | $0 | -$359.6M | N/A | $3.9B | — |
Where Centessa Pharmaceuticals Plc Ranks
Frequently Asked Questions
What is Centessa Pharmaceuticals Plc's annual revenue?
Centessa Pharmaceuticals Plc (CNTA) reported $15.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Centessa Pharmaceuticals Plc profitable?
No, Centessa Pharmaceuticals Plc (CNTA) reported a net income of -$197.5M in fiscal year 2025.
What is Centessa Pharmaceuticals Plc's EBITDA?
Centessa Pharmaceuticals Plc (CNTA) had EBITDA of -$206.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Centessa Pharmaceuticals Plc have?
As of fiscal year 2025, Centessa Pharmaceuticals Plc (CNTA) had $61.3M in cash and equivalents against $110.1M in long-term debt.
What is Centessa Pharmaceuticals Plc's return on equity (ROE)?
Centessa Pharmaceuticals Plc (CNTA) has a return on equity of -37.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Centessa Pharmaceuticals Plc's free cash flow?
Centessa Pharmaceuticals Plc (CNTA) recorded an outflow of $194.2M in free cash flow during fiscal year 2025. This represents a -36.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Centessa Pharmaceuticals Plc's operating cash flow?
Centessa Pharmaceuticals Plc (CNTA) recorded an outflow of $193.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Centessa Pharmaceuticals Plc's total assets?
Centessa Pharmaceuticals Plc (CNTA) had $687.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Centessa Pharmaceuticals Plc's capital expenditures?
Centessa Pharmaceuticals Plc (CNTA) invested $371K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Centessa Pharmaceuticals Plc spend on research and development?
Centessa Pharmaceuticals Plc (CNTA) invested $172.2M in research and development during fiscal year 2025.
What is Centessa Pharmaceuticals Plc's current ratio?
Centessa Pharmaceuticals Plc (CNTA) had a current ratio of 8.57 as of fiscal year 2025, which is generally considered healthy.
What is Centessa Pharmaceuticals Plc's debt-to-equity ratio?
Centessa Pharmaceuticals Plc (CNTA) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Centessa Pharmaceuticals Plc's return on assets (ROA)?
Centessa Pharmaceuticals Plc (CNTA) had a return on assets of -28.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Centessa Pharmaceuticals Plc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Centessa Pharmaceuticals Plc (CNTA) held $577.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $193.8M over that year. Dividing the one by the other, the reported balance equals about 36 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Centessa Pharmaceuticals Plc's Altman Z-Score?
Centessa Pharmaceuticals Plc (CNTA) has an Altman Z-Score of 20.58, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Centessa Pharmaceuticals Plc's Piotroski F-Score?
Centessa Pharmaceuticals Plc (CNTA) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Centessa Pharmaceuticals Plc's earnings high quality?
Centessa Pharmaceuticals Plc (CNTA) reported a net loss of $197.5M while operations used $193.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Centessa Pharmaceuticals Plc cover its interest payments?
Centessa Pharmaceuticals Plc (CNTA) reported an operating loss of $207.7M against $11.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Centessa Pharmaceuticals Plc?
Centessa Pharmaceuticals Plc (CNTA) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.